[3] Gelber DA. et al. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke. 2001. 32(8):1841-1846.
[4] Francisco GE et al. Consensus panel guidelines for the use of intrathecal baclofen therapy in poststroke spastic hypertonia. Top Stroke Rehabil. 2006;13(4):74-85.
[5] The World Health Organisation: Atlas of Heart Disease and Stroke 2004. Disponible en: http://www.who.int/cardiovascular_diseas...
[6] Truelsen T. et al. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol. 2006. 13(6):581-598.
[7] Welmer AK. et al. Spasticity and its association with functioning and health-related quality of life 18 months after stroke. Cerebrovasc Dis. 2006;21(4):247-53.
[8] Ivanhoe CB, et al. Intrathecal baclofen management of poststroke spastic hypertonia: implications for function and quality of life. Arch Phys Med Rehabil. 2006. 87(11):1509-15.
[9] Penn RD, et al. Intrathecal baclofen for severe spinal spasticity. New England Journal of Medicine 1989;320:1517-21
[10] Meythaler JM, et al. Intrathecal baclofen for spastic hypertonia from stroke. Stroke. 2001. 32(9):2099-109
[11] Sampson FC et al. Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity. J of Neurosur 2002; 96(6): 1052-1507.
[12] Creedon SD, et al. Intrathecal baclofen for severe spasticity: a meta-analysis. Int J Rehabil Health 1997; 3(3):171-85.
[13] Bensmail D. et al. Cost-effectiveness modeling of Intrathecal Baclofen Therapy Versus Other Interventions for Disabling Spasticity. Neurohabil Neural Repair. 2009. Febr. 1-7
[14] Datos de archivo de Medtronic
Contactos: Jeff Warren, Relaciones para inversores, +1-763-505-2696; Jon Pike, Relaciones públicas, +44-7825-889-607
